[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unresectable-stage-iii-non-small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unresectable-stage-iii-non-small-cell-lung-cancer":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100636153","phase-2-tislelizumab-plus-chemotherapy-and-bace-for-unresectable-nsclc-100636153",false,"NCT07561983","Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC","Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)","BEACON-Lung","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)\n* Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system\n* Initially unresectable disease as determined by multidisciplinary team (MDT) assessment\n* At least 1 measurable intrapulmonary lesion according to RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Forced expiratory volume in the first second (FEV1) \\> 1.0 L and \\> 40% of predicted normal value\n* Estimated life expectancy of at least 3 months\n* Adequate organ function\n* Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment\n* Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Ability to understand and willingness to sign a written informed consent form\n\nExclusion Criteria:\n\n* Prior local therapy for NSCLC, including radiotherapy or interventional therapy\n* Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations\n* Distant organ metastasis\n* History of another malignancy within the past 5 years\n* Active autoimmune disease or history of autoimmune disease requiring systemic treatment\n* Known allergy to any study drug or excipient\n* Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment\n* Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis\n* Major surgery requiring general anesthesia within 4 weeks before first dose\n* Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk\n* Participation in another interventional therapeutic clinical study\n* Psychiatric illness or history of psychotropic drug abuse that may compromise study participation\n* Any condition judged by the investigator to make the patient unsuitable for the study","ALL","18 Years","80 Years",{"count":21,"type":22},39,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are:\n\n* What is the 1-year event-free survival (EFS) rate with this treatment?\n* Can this treatment improve tumor response and the chance of curative-intent resection?\n* What adverse events occur during treatment?\n\nParticipants will receive tislelizumab, intravenous chemotherapy, and BACE for up to 4 cycles. Tumor response and resectability will be evaluated by imaging and multidisciplinary team (MDT) assessment every 2 cycles. Participants who become resectable may undergo surgery followed by postoperative treatment per protocol. Participants who remain unresectable after 4 cycles will receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation. Regular follow-up will be performed for efficacy and safety assessment.",[28,29,30,31,32],"Unresectable Stage III Non-small Cell Lung Cancer","Tislelizumab","Chemotherapy","Chemoembolization, Therapeutic","Conversion Therapy",[34,29,30,35,32],"Unresectable Non-Small Cell Lung Cancer","Bronchial Artery Chemoembolization","NOT_YET_RECRUITING","2026-04-24",{"date":39,"type":40},"2026-05-01","ACTUAL",{"date":39,"type":22},{"date":43,"type":22},"2028-12-31",{"name":45,"class":46},"Sichuan Cancer Hospital and Research Institute","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100624361","phase-2-ibi363-pd-1il-2-bias-in-combination-with-chemotherapy-as-neoadjuvant-therapy-in-initially-unresectable-stage-iii-non-small-cell-lung-cancer-100624361","NCT07408635","IBI363 (PD-1\u002FIL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer","IBI363 (PD-1\u002FIL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy to Convert Initially Unresectable Stage III Non-Small Cell Lung Cancer To Resectable Disease: a Phase II, Single-Arm Clinical Trial","INCLUSION CRITERIA\n\n1. The patient shall sign the informed consent.\n2. Age ≥ 18 years.\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n4. Histologically or cytologically confirmed Stage III (per AJCC 9th) squamous or non-squamous non-small-cell lung cancer (NSCLC) deemed unresectable by the investigator.\n5. Tumours with mixed NSCLC histology must be categorised as either squamous or non-squamous on the basis of the predominant component. Tumours containing both NSCLC and small-cell lung cancer (SCLC) are excluded.\n6. \"Unresectable\" is defined as following: (1) Multistation or confluent metastasis in ipsilateral mediastinal lymph nodes (2)Contralateral or supraclavicular lymph node metastasis (N3) (3)Invasion of critical organs or major blood vessels (4)Extensive invasion of the chest wall and pleura (5)Special anatomical locations (6）Patient intolerance to lobectomy or pneumonectomy.\n7. At least one measurable lesion per RECIST v1.1.\n8. Adequate organ function meet the following standards (within 14 days before first dose, any blood components or growth factor drugs is not permitted):\n\n   * ANC count ≥ 1.5 × 10⁹\u002FL\n   * Platelet count ≥ 100 × 10⁹\u002FL\n   * Hemoglobin ≥ 90 g\u002FL\n   * Serum Cr ≤ 1.5 times of upper limit of normal (ULN) or calculated creatinine clearance (CLcr) ≥ 50 mL\u002Fmin\n   * Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in Gilbert's syndrome)\n   * AST and ALT ≤ 2.5 × ULN\n   * INR or APPT ≤ 1.5 × ULN\n   * left ventricular ejection fraction (LVEF) ≥ 50 %\n9. Contraception and reproductive status:\n10. Fertile female patients must voluntarily use effective contraception during the study period and for at least 3 months after treatment completion, and urine or serum pregnancy test result within 72 hours prior to enrollment are negative and must not be breastfeeding. Male patients with female partners of childbearing potential must use effective contraception during the trial and for 3 months after the last dose of IBI363.\n\nEXCLUSION CRITERIA\n\n1. Non-squamous and squamous NSCLC with EGFR active mutation positive, ALK rearrangement, or any other driver mutation with an approved targeted therapy.\n2. History of other malignant tumors within five years or concurrently present, except adequately treated cervical carcinoma in situ, basal- or squamous-cell skin carcinoma, localized prostate cancer after radical prostatectomy, ductal carcinoma in situ after radical prostatectomy, or other tumor deemed cured by the investigator.\n3. Histologically confirmed the presence of small cell lung cancer component.\n4. Participants who have received any systemic anti-cancer treatment.\n5. Clinically significant cardiovascular or cerebrovascular disease, including:\n\n   1. Myocardial infarction or unstable angina within 6 months before first dose\n   2. Stroke or transient ischaemic attack within 6 months before first dose\n   3. Uncontrolled hypertension (systolic ≥ 160 mmHg and\u002For diastolic ≥ 100 mmHg) despite optimal therapy\n   4. Congestive heart failure (NYHA class III-IV)\n   5. Myocarditis\n6. Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids \\>10 mg\u002F day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy are permitted.\n7. Presence of any active autoimmune disease or history of autoimmune disease.\n8. Idiopathic pulmonary fibrosis, organizing pneumonia, drug pneumonia, or active pneumonia shown on CT during screening period have been or are currently present.\n9. History of allogeneic haematopoietic stem-cell or solid-organ transplantation.\n10. The subject has congenital or acquired immune deficiency (such as HIV infected persons).\n11. Active hepatitis (HBsAg positive and HBV DNA \\>the upper limit of normal value; HCV antibody and HCV RNA positive. Subjects who meet the following criteria may be enrolled: HBV-DNA \\\u003C500 IU\u002FmL measured within 28 days prior to study dosing, have received at least 4 weeks of standard antiviral therapy, and are willing to continue antiviral therapy throughout the study period.)\n12. Participants who are allergic to the test drug or any auxiliary materials.\n13. The vaccine was administered within 30 days before first dose or planned during treatment and up to 90 days after the last dose.\n14. Severe active infection within 2 weeks before first dose.\n15. Other factors that may increase study risk, interfere with results, or render the patient unsuitable per investigator judgment.",{"count":56,"type":22},43,[25],"This study is a single-arm, phase II clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a neoadjuvant treatment of non-small cell lung cancer.",[28,60],"Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)","RECRUITING","2026-02-12",{"date":64,"type":40},"2026-02-13",{"date":66,"type":40},"2026-01-07",{"date":68,"type":22},"2030-01-06",{"name":70,"class":46},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100561572","induction-therapy-with-serplulimab-combined-with-chemotherapy-for-unresectable-stage-iii-non-small-cell-lung-cancer-100561572","NCT06591910","Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer","Induction Therapy With Serplulimab Combined With Chemotherapy Followed by Local Therapy for Unresectable Stage III Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. The patient shall sign the Informed Consent Form.\n2. Aged 18 ≥ years.\n3. Histological or cytological diagnosis of unresectable NSCLC by needle biopsy, and stage III (8th TNM) confirmed by imageological examinations (CT, PET-CT or EBUS).\n4. Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1.\n5. Life expectancy is at least 12 weeks.\n6. At least 1 measurable lesion according to RECIST 1.1.\n7. Patients with good function of other main organs (liver, kidney, blood system, etc.)\n8. Patients with normal lung function can tolerate surgery;\n9. Without systematic metastasis (including M1a, M1b and M1c);\n10. Fertile female patients must voluntarily use effective contraceptives not less than 120 days after chemotherapy or the last dose of Serplulimab (whichever is later) during the study period, and urine or serum pregnancy test results within 7 days prior to enrollment are negative.\n11. Unsterilized male patients must voluntarily use effective contraception during the study period not less than 120 days after chemotherapy or the last dose of Serplulimab (whichever is later).\n\nExclusion Criteria:\n\n1. Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment;\n2. Participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (\\>= NYHA) Grade II), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;\n3. With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;\n4. Participants who are allergic to the test drug or any auxiliary materials;\n5. Participants with Interstitial lung disease currently;\n6. Participants with active hepatitis B, hepatitis C or HIV;\n7. Pregnant or lactating women;\n8. Participants suffering from nervous system diseases or mental diseases that cannot cooperate;\n9. Participated in another therapeutic clinical study;\n10. Other factors that researchers think it is not suitable for enrollment.",{"count":79,"type":22},50,"5 Years","OBSERVATIONAL","For unresectable stage III (8th TNM) non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial. However, it is unclear whether induction chemoimmunotherapy followed by surgery or radiotherapy can provide good survival for this population. This prospective observational study aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery\u002Fradiotherapy.",[84],"Unresectable Stage III Non-small-cell Lung Cancer",[86,87,88,89],"unresectable","stage III","non-small cell lung cancer","chemoimmunotherapy","2024-09-08",{"date":92,"type":40},"2024-09-19",{"date":94,"type":22},"2024-09-20",{"date":96,"type":22},"2030-09-20",{"name":70,"class":46}]